



REVIEW

Cytomegalovirus in pregnancy and the neonate [version 1; referees: 2 approved]

Vincent C. Emery ¹, Tiziana Lazzarotto²

¹Department of Microbial and Cellular Sciences, School of Biosciences and Medicine, University of Surrey, Guildford, Surrey, UK

²Department of Specialized, Experimental and Diagnostic Medicine, University of Bologna, Bologna, Italy

v1 **First published:** 14 Feb 2017, 6(F1000 Faculty Rev):138 (doi: 10.12688/f1000research.10276.1)


Latest published: 14 Feb 2017, 6(F1000 Faculty Rev):138 (doi: 10.12688/f1000research.10276.1)

Abstract

Congenital cytomegalovirus (CMV) remains a leading cause of disability in children. Understanding the pathogenesis of infection from the mother via the placenta to the neonate is crucial if we are to produce new interventions and provide supportive mechanisms to improve the outcome of congenitally infected children. In recent years, some major goals have been achieved, including the diagnosis of primary maternal CMV infection in pregnant women by using the anti-CMV IgG avidity test and the diagnosis and prognosis of foetal CMV infection by using polymerase chain reaction real-time tests to detect and quantify the virus in amniotic fluid. This review summarises recent advances in our understanding and highlights where challenges remain, especially in vaccine development and anti-viral therapy of the pregnant woman and the neonate. Currently, no therapeutic options during pregnancy are available except those undergoing clinical trials, whereas valganciclovir treatment is recommended for congenitally infected neonates with moderately to severely symptomatic disease.

Open Peer Review

Referee Status:  

	Invited Referees	
	1	2
version 1 published 14 Feb 2017		

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty. In order to make these reviews as comprehensive and accessible as possible, peer review takes place before publication; the referees are listed below, but their reports are not formally published.

- 1 **William Rawlinson**, Prince of Wales Hospital Australia, University of New South Wales Australia
- 2 **David Abate**, University of Padua Italy

Discuss this article

Comments (0)

Corresponding author: Vincent C. Emery (v.emery@surrey.ac.uk)

How to cite this article: Emery VC and Lazzarotto T. **Cytomegalovirus in pregnancy and the neonate [version 1; referees: 2 approved]** *F1000Research* 2017, **6**(F1000 Faculty Rev):138 (doi: [10.12688/f1000research.10276.1](https://doi.org/10.12688/f1000research.10276.1))

Copyright: © 2017 Emery VC and Lazzarotto T. This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Competing interests: The authors declare that they have no competing interests.

First published: 14 Feb 2017, **6**(F1000 Faculty Rev):138 (doi: [10.12688/f1000research.10276.1](https://doi.org/10.12688/f1000research.10276.1))

Introduction

Cytomegalovirus (CMV) remains a major cause of congenital infection and disease during pregnancy around the world¹. Our understanding of the pathogenesis of CMV during pregnancy continues to improve through the application of new technologies and interventional studies. However, there remain a number of outstanding questions relating to CMV infection in pregnancy, especially in the context of women who are already seropositive for CMV where multiple strains may be present in the face of a strong T- and B-cell immune response, the comparative pathogenesis in developed and developing countries, and the optimal therapeutic strategies to be deployed. Recently, there has been significant interest in establishing associations between genetic variants and strain pathogenicity of CMV. In 2013, Renzette *et al.* created the most detailed map of human CMV *in vivo* evolution to date and demonstrated that viral populations can be stable or rapidly differentiate, depending on the host environment². Furthermore, in 2015, Sijmons *et al.* provided an important compendium of data concerning human CMV strain diversity³. These studies support the hypothesis that human CMV strains may vary in virulence, tropism, and pathogenic potential, which in turn is probably related to the genetic variability exhibited in key genes important for pathogenesis among wild-type CMV strains. Identification of specific, more highly pathogenic, CMV variants could provide clinically useful information³.

The present article will survey the progress that has been made in these areas, particularly over the last 4 years, and provide a succinct update on how our understanding of CMV in pregnancy has matured in recent years and the potentially beneficial effects of antiviral therapy in managing congenital CMV infection and disease.

Cytomegalovirus in pregnancy: risk factors and epidemiology

CMV seroprevalence across the globe varies substantially both between and within countries^{4–7} (Figure 1). As a rule of thumb, lower socioeconomic groups have a higher incidence of CMV exposure and resource-poor countries also have higher seroprevalence levels with infection (from 84% to 100% IgG-positive) frequently acquired early in life⁸. These epidemiological patterns have a direct impact on the incidence of congenital infection and disease. For example, the classic high-risk setting for congenital CMV infection and particularly disease is where a seronegative mother becomes infected during pregnancy (in particular, during the first trimester) and transmits the virus to the foetus. In this situation, transmission to the foetus occurs in 30–35% of cases and congenital disease in around 10–15% of those born with congenital infection⁶. In contrast, in women who are already seropositive, reactivation or reinfection gives rise to a foetal infection rate of about 1.2%, which whilst much lower than primary infection acts to be the main contributor to the total number of congenital infections (and disease) worldwide^{9–11}. Lastly, increasing observations demonstrate the risk for symptomatic infection at birth, and sequelae, especially hearing loss, are similar upon primary and non-primary maternal CMV infection^{8,12–15}.

In terms of pathogenesis, in children with symptomatic disease, approximately 4% will die *in utero* or shortly after birth and this is usually because of significant neurological damage and multi-organ failure¹⁶. Of the remainder, about 60% will have cognitive defects; sensorineural hearing loss (SNHL) and neurological impairment are two common manifestations¹⁶. Indeed, SNHL, which is prevalent at about 35%, is a progressive disease, and, even in




Figure 1. Global cytomegalovirus (CMV) seroprevalence levels and incidence of congenital CMV infection. Worldwide CMV seroprevalence rates among women of reproductive age and birth prevalence of congenital CMV infection (reproduced from 1). CMV seroprevalence rates are shown in different shades of colour, and congenital CMV birth prevalence rates are shown by the circles.

neonates born with asymptomatic infection, there is now increasing evidence that a significant subset of these will develop SNHL^{17–19}. Thus, early identification of children at risk of progressive SNHL is a priority, as interventions may provide a substantial benefit (an aspect that will be discussed later).

In CMV seropositive women, the risk factors for congenital infection are less well defined, although in a recent study of pregnant Polish women, around 22% of seropositive women who transmitted to their neonate were infected with multiple CMV strains as judged by glycoprotein B genotyping²⁰. Additional studies by targeted sequencing demonstrated that other genes of CMV have highly variable regions including proteins gN, gO, gH, and UL144^{2,3}. However, the role that mixed genotype infection plays in transmission and the immune response against these different strains has not been fully investigated.

In healthy humans, the T-cell immune response against CMV is both multi-specific and high frequency in both CD4 and CD8 compartments²¹. In many studies of transplant recipients, a high frequency of functional (that is, interferon gamma [IFN- γ]-producing) CMV-specific CD8 together with CD4 helper cells has been shown to be protective against high-level CMV replication and also disease^{22–25}. Thus, the assumption might be that in pregnant women a similar T-cell phenotype may be protective against CMV disease. Recent data question this hypothesis; with IFN- γ ELISpot assay and CMV IgG avidity testing, it was shown that women who transmitted to their offspring were more likely to have a higher T-cell response and that the combination of low CMV IgG avidity and high ELISpot values gave an area under the curve of 0.87²⁶.

Eldar-Yedidia *et al.* proposed a novel normalisation method testing the individual IFN- γ response to CMV (IFN- γ relative response, or RR) detected by the QuantiFERON assay and found that the group of women with a low CMV IFN- γ RR did not transmit the virus to the foetus²⁷. However, Forner *et al.* showed that the results of CMV cell-mediated immunity obtained with the ELISpot assay were more significantly associated with the risk of CMV transmission compared with those obtained with the QuantiFERON test²⁸. Further studies in a larger number of CMV-infected pregnant women should be performed in order to verify the prognostic efficacy of determining the maternal CMV-specific T-cell immune response. Finally, data using a Rhesus animal model of CMV have clearly demonstrated that, in the absence of CD4 T cells, more severe CMV disease was observed in the offspring²⁹.

Advances in screening for cytomegalovirus in pregnancy

Screening of mothers for CMV IgG on a routine basis has not been universally adopted, although at present eight European countries have adopted a *de facto* screening^{30,31}. One of the stated reasons why such an approach is not warranted is the incidence of congenital infection and disease amongst children born to women who are already CMV IgG positive. However, if there is clinical suspicion of primary CMV infection, appropriate testing of antenatal samples for seroconversion and investigating IgG avidity

levels are standard practice³². To assess the risk of transmission to the foetus, prenatal testing of amniotic fluid at 20–21 weeks of gestation by real-time polymerase chain reaction (PCR) has also been investigated^{33–40}. The foetal CMV diagnosis is reliable: a negative result in the amniotic fluid can rule out foetal infection with a high degree of certainty. Positive results in amniotic fluid identify CMV-infected foetuses but do not discriminate those infants who will have symptoms at birth. Studies have shown that low viral loads in amniotic fluid are associated with a lower risk of congenital disease, but it is clear that the positive and negative predictive values of qualitative and quantitative PCR on amniotic fluid are not sufficiently robust for routine deployment and should be considered with caution^{41,42}.

Advances in understanding the role of the placenta in infection

In recent years, our understanding of the complex interaction between the placenta and CMV and how it relates to congenital infection has improved significantly. Of particular note here is the work of the Pereira group. The recent observations show that CMV particularly infects amniotic membranes⁴³, impairs cytotrophoblast-induced lymphangiogenesis and vascular remodelling in the placenta, and arrests the correct development of human trophoblast progenitor cells, thus interfering with the earliest stages in the growth of new villi. This results in increased hypoxia, which ultimately contributes to restriction in foetal growth⁴⁴. In fact, immunohistochemical and virological studies of placental tissues suggested that severe placental infection was associated with diffuse villitis and necrosis, consistent with functional impairment and possible consequent hypoxic cerebral damage⁴⁵.

CMV infection also appears to persist in the amniotic epithelial cells and has been associated with increased expression of the anti-apoptotic proteins *survivin* and Bclx-1 through both STAT-3-dependent and -independent mechanisms⁴⁶. In addition, CMV has been shown to inhibit Wnt5a-stimulated migration of trophoblasts through increasing the expression of the WNT receptor ROR2⁴⁷.

CMV infection induces an innate immune response in the placenta, significantly altering the decidual cytokine and chemokine environment. In particular, Hamilton *et al.* highlighted how CMV infection modulates the placental immune environment, suggesting CMV-induced upregulation of monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis factor-alpha (TNF- α) expression as a potential initiator or exacerbator (or both) of placental and foetal injury⁴⁸. In CMV-infected decidual cultures, there is a predominant induction of INF- γ and inducible protein 1 (IP-1) expression, reflecting the immune activation generated upon CMV infection⁴⁹.

Advances in risk stratification of infected neonates

A comprehensive analysis by Cannon *et al.*⁵⁰ assessed each of the sequelae of congenital CMV and the evidence for different interventions making a positive impact. This study concluded that there was good evidence that non-pharmaceutical interventions for children with delayed hearing loss by 9 months of age would have an impact and that a moderate effect of pharmaceutical interventions would be observed on hearing loss between 9 and

24 months and on CMV-related cognitive deficits. However, the evidence for interventions affecting children with hearing loss of neurological impairment occurring after 24 months was weak. On this basis, the authors proposed that a combination of newborn screening and early detection and interventions would benefit thousands of children with congenital CMV in the USA alone.

At present, no European country routinely screens for congenital CMV infection. In four states in the USA, the efforts of non-profit organisations have determined the introduction and passage of legislation for infant CMV screening. Attention over the last decade has turned to the use of dried blood spots, since these are routinely taken to diagnose biochemical and genetic disorders in the newborn. However, the sensitivity of this approach using PCR-based detection methods is highly variable (28–100%), even when large sample sizes have been used^{51–53}. Further improvements in sensitivity can be achieved by standardised procedures of viral DNA extraction and nested PCR approaches, with a recent article showing a sensitivity of 81%⁵⁴. As an alternative, saliva has been suggested as the sample of choice, but this would require a different sample to be taken at birth, and for routine screening this may prove to be too complex and costly to adopt⁵⁵.

Impact of co-infections on cytomegalovirus in pregnancy

A major co-infection which impacts directly on CMV in pregnancy is HIV infection. Recent data highlight that HIV-1/CMV co-infected infants have a high risk of mortality, neurological defects, and HIV disease progression^{56,57}. Rates of congenital CMV infection in HIV-exposed but uninfected infants in Nairobi have been shown to be 6.3% and this increased to 29% if the infant was HIV infected⁵⁸. To date, no large systematic studies have investigated the transmission frequency in HIV-infected women of CMV to the neonate in the context of both maternal CMV infection during pregnancy versus post-partum infection, which is known to be prominent through CMV in breast milk. However, one study has used data from a valacyclovir interventional study (for herpes simplex virus [HSV] infection) to investigate its effects on infant CMV acquisition⁵⁹. Valacyclovir at the doses used for HSV-1 control has a relatively weak anti-viral effect on CMV replication. The upshot of this study was that maternal valacyclovir use had no effect on the timing or acquisition of infant CMV or on breast milk viral loads but that it did reduce cervical CMV shedding. Further studies using high-dose valacyclovir or safer anti-CMV drugs would be warranted in this patient group⁶⁰. It has also been shown that maternal highly active anti-retroviral therapy (HAART) can reduce vertical transmission of CMV but does not reduce breast milk levels and so would be unlikely to impact on post-natal infection⁶¹.

Advances in anti-viral therapy

The most extensive study to date on the use of anti-viral therapy for symptomatic CMV disease was published in 2015⁶². The study enrolled 96 neonates who were randomly assigned to either 6 months or 6 weeks of valganciclovir therapy. The primary endpoint (best ear audiological improvement) was similar between the two arms, although total ear hearing was more likely to have improved and be stable at 12 months in the 6-month valganciclovir

arm. Interestingly, the 6-month treatment arm was also associated with significant improvements ($P < 0.004$) in neurodevelopmental scores (improvement in the language-composite component and the receptive-communication scale). This study builds on a previous anti-viral study of intravenous ganciclovir⁶³ and, though encouraging, shows that until we have access to anti-CMV drugs with greater potency and improved side-effect profiles, it is unlikely that this area will move forward rapidly. Currently, valganciclovir treatment for 6 months is recommended for congenitally infected neonates with moderate to severe CMV disease and should be started within the first month of life.

At present, there is no evidence for the potential benefit of treatment of asymptomatic infants or asymptotically infected children with isolated sensorineural hearing loss (≥ 20 dB in one or both ears)^{62,64}. One non-randomised, single-blind clinical trial is currently investigating whether early treatment with valganciclovir of infants up to 12 weeks of age with both congenital CMV infection and SNHL can prevent progression of hearing loss (ClinicalTrials.gov identifier NCT02005822). Two other clinical trials are being undertaken in order to provide evidence for treatment options in congenitally CMV-infected newborns (ClinicalTrials.gov identifiers NCT01649869 and NCT02606266).

A preliminary report on an open-label phase II study of *in utero* treatment of congenital CMV with high-dose valacyclovir (8 g/day) has recently been published. The interim analysis indicates that longer-term exposure to valacyclovir (median of 89 days) decreases foetal viral loads significantly and combined with historical controls decreases the proportion of symptomatic neonates from 57% to 18%⁶⁰. However, the trial design using historical controls is not optimal and so further, more substantial analysis of this ongoing study is required and there is a need for others to replicate the study design in a controlled way.

Vaccine development and its potential impact

The basic reproductive number (R_0) for CMV for infections occurring in the developed world is around 2.4, meaning that for herd immunity a vaccine update rate (assuming 100% efficacy) would need to be 59–62% to achieve eradication⁶⁵. Modelling has shown that if vaccination was started in all toddlers and children aged 12, after 4 years a decline in infected babies occurs (owing to girls immunised at age 12 starting to enter child-bearing age) but that a more rapid decline is observed for babies with congenital infection born to seronegative women and also seropositive women who become re-infected during pregnancy⁶⁶. To date, only a recombinant CMV glycoprotein B (gB) vaccine administered with the adjuvant MF59 has been evaluated in seronegative women; the vaccine showed an approximately 50% reduction in maternal infection in women vaccinated⁶⁷. This phase 2 study also observed one congenital infection in the vaccine group compared with three in the placebo arm, although the sample size prevented statistically valid analysis of this observation.

Very recently, a study performed in a guinea pig model demonstrated that immunisation with a novel bivalent vaccine based on a non-replicating lymphocytic choriomeningitis virus (LCMV)

vector expressing gB and pp65 did not show interference. Moreover, the bivalent vaccine elicited potent humoral and cellular responses and conferred protection, reducing the magnitude of maternal viremia and improving pup outcomes. These results support further testing of LCMV-vector-based human CMV vaccines in clinical trials⁶⁸.

An alternative approach using hyperimmune globulin to prevent congenital CMV has also been subjected to a randomised controlled trial⁶⁹. In this study, 124 pregnant women with primary CMV infection at 5–26 weeks of gestation were randomly assigned to hyperimmune globulin or placebo every 4 weeks until 36 weeks of gestation or until CMV was detected in amniotic fluid. The rate of congenital infection was comparable between the two groups (hyperimmune globulin 33%, placebo 44%; $P = 0.13$). Hyperimmune globulin had no effect on maternal CMV DNA levels in the blood or in time to clearance of DNA from the blood and did not impact on CMV DNA levels in the placenta. However, the results of this randomised placebo-controlled trial showed no agreement with those from a non-randomised study published in 2005 by Nigro *et al.*, who showed that the administration of CMV-specific hyperimmune globulin to pregnant women with primary infection significantly decreased the rate of mother-to-foetus transmission, from 40% to 16% ($P = 0.04$)⁷⁰. Further studies are needed given the biological plausibility of this approach⁷⁰.

Currently, two randomised, phase 3 studies of the prevention of congenital infection are underway. One, sponsored by Biotest, is being conducted in Europe, and the second, sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, is ongoing in the USA (ClinicalTrials.gov identifier NCT01376778).

The hope is that these studies will further aid our understanding of the efficacy and safety of hyperimmune globulin administration as a means of preventing congenital CMV infection.

A systematic review published by Hamilton *et al.* highlighted how, despite a number of case series and case control and observational studies, there is a significant lack of robust clinical trial data examining prophylactic interventions for congenital CMV infection⁷¹.

Conclusions and future prospects

The last few years have seen real progress in understanding the basic biology of CMV in the placenta and the role that ongoing viral replication plays in the pathogenesis of CMV disease in the neonate. However, for a variety of reasons, screening of pregnant women for CMV, whilst supported, has not been implemented globally, and routine surveillance of neonates for evidence of CMV infection requires new methodologies or improvement of the current ones, especially with respect to simpler protocols and lower costs. The therapy of the newborn infant with CMV shows promise, but we need safer and preferably more potent drugs to make a large impact; new drugs such as letermovir are on the horizon, as are active vaccine development programmes, making the future of CMV in pregnancy a very active area of basic and translational research.

Abbreviations

CMV, cytomegalovirus; gB, glycoprotein B; HSV, herpes simplex virus; IFN- γ , interferon-gamma; LCMV, lymphocytic choriomeningitis virus; PCR, polymerase chain reaction; Ro, basic reproductive number; ROR2, receptor tyrosine kinase-like orphan receptor; RR, relative response; SNHL, sensory neural hearing loss; STAT, signal transducer and activator of transcription.

Competing interests

The authors declare that they have no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References



- Manicklal S, Emery VC, Lazzarotto T, *et al.*: **The "silent" global burden of congenital cytomegalovirus.** *Clin Microbiol Rev.* 2013; **26**(1): 86–102. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- F** Renzette N, Gibson L, Bhattacharjee B, *et al.*: **Rapid intra-host evolution of human cytomegalovirus is shaped by demography and positive selection.** *PLoS Genet.* 2013; **9**(9): e1003735. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- F** Sijmons S, Thys K, Mbong Ngwese M, *et al.*: **High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination.** *J Virol.* 2015; **89**(15): 7673–7695, pii: JVI.00578-15. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Cannon MJ: **Congenital cytomegalovirus (CMV) epidemiology and awareness.** *J Clin Virol.* 2009; **46**(Suppl 4): S6–10. [PubMed Abstract](#) | [Publisher Full Text](#)
- Cannon MJ, Schmid DS, Hyde TB: **Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection.** *Rev Med Virol.* 2010; **20**(4): 202–13. [PubMed Abstract](#) | [Publisher Full Text](#)
- Kenneson A, Cannon MJ: **Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection.** *Rev Med Virol.* 2007; **17**(4): 253–76. [PubMed Abstract](#) | [Publisher Full Text](#)
- Marshall GS, Stout GG: **Cytomegalovirus seroprevalence among women of childbearing age during a 10-year period.** *Am J Perinatol.* 2005; **22**(7): 371–6. [PubMed Abstract](#) | [Publisher Full Text](#)
- F** Lanzieri TM, Dollard SC, Bialek SR, *et al.*: **Systematic review of the birth prevalence of congenital cytomegalovirus infection in developing countries.** *Int J Infect Dis.* 2014; **22**: 44–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Stagno S, Pass RF, Dworsky ME, *et al.*: **Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infection.** *N Engl J Med.* 1982; **306**(16): 945–9. [PubMed Abstract](#) | [Publisher Full Text](#)
- Wang C, Zhang X, Bialek S, *et al.*: **Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection.** *Clin Infect Dis.* 2011; **52**(2): e11–3. [PubMed Abstract](#) | [Publisher Full Text](#)
- Ornoy A, Diav-Citrin O: **Fetal effects of primary and secondary cytomegalovirus infection in pregnancy.** *Reprod Toxicol.* 2006; **21**(4): 399–409. [PubMed Abstract](#) | [Publisher Full Text](#)
- Gaytan MA, Rours GI, Steegers EA, *et al.*: **Congenital cytomegalovirus infection**

- after recurrent infection: case reports and review of the literature. *Eur J Pediatr*. 2003; 162(4): 248–53.
[PubMed Abstract](#)
13. Zalel Y, Gilboa Y, Berkenshtat M, *et al.*: Secondary cytomegalovirus infection can cause severe fetal sequelae despite maternal preconceptional immunity. *Ultrasound Obstet Gynecol*. 2008; 31(4): 417–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
 14. Mussi-Pinhata MM, Yamamoto AY, Moura Brito RM, *et al.*: Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. *Clin Infect Dis*. 2009; 49(4): 522–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 15. Yamamoto AY, Mussi-Pinhata MM, Isaac Mde L, *et al.*: Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly immune population. *Pediatr Infect Dis J*. 2011; 30(12): 1043–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 16. Dollard SC, Grosse SD, Ross DS: New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. *Rev Med Virol*. 2007; 17(5): 355–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
 17. Grosse SD, Ross DS, Dollard SC: Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. *J Clin Virol*. 2008; 41(2): 57–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
 18. Dahle AJ, Fowler KB, Wright JD, *et al.*: Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. *J Am Acad Audiol*. 2000; 11(5): 283–90.
[PubMed Abstract](#)
 19. Fowler KB, Dahle AJ, Boppana SB, *et al.*: Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed? *J Pediatr*. 1999; 135(1): 60–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 20. **F** Ryceł M, Wujcicka W, Zawilńska B, *et al.*: Mixed infections with distinct cytomegalovirus glycoprotein B genotypes in Polish pregnant women, fetuses, and newborns. *Eur J Clin Microbiol Infect Dis*. 2015; 34(3): 585–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 21. **F** Sylwester AW, Mitchell BL, Edgar JB, *et al.*: Broadly targeted human cytomegalovirus-specific CD4⁺ and CD8⁺ T cells dominate the memory compartments of exposed subjects. *J Exp Med*. 2005; 202(5): 673–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 22. Mattes FM, Vargas A, Kopycinski J, *et al.*: Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. *Am J Transplant*. 2008; 8(5): 990–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. Nebbia G, Mattes FM, Smith C, *et al.*: Polyfunctional cytomegalovirus-specific CD4⁺ and pp65 CD8⁺ T cells protect against high-level replication after liver transplantation. *Am J Transplant*. 2008; 8(12): 2590–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. Crough T, Fazou C, Weiss J, *et al.*: Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8⁺ T-cell response. *J Virol*. 2007; 81(20): 11538–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 25. **F** Manuel O, Husain S, Kumar D, *et al.*: Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. *Clin Infect Dis*. 2013; 56(6): 817–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 26. **F** Saldan A, Forner G, Mengoli C, *et al.*: Strong Cell-Mediated Immune Response to Human Cytomegalovirus Is Associated With Increased Risk of Fetal Infection in Primarily Infected Pregnant Women. *Clin Infect Dis*. 2015; 61(8): 1228–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 27. **F** Eldar-Yedidia Y, Bar-Meir M, Hillel M, *et al.*: Low Interferon Relative-Response to Cytomegalovirus Is Associated with Low Likelihood of Intrauterine Transmission of the Virus. *PLoS One*. 2016; 11(2): e0147883.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 28. **F** Forner G, Saldan A, Mengoli C, *et al.*: Cytomegalovirus (CMV) Enzyme-Linked Immunosorbent Spot Assay but Not CMV QuantiFERON Assay Is a Novel Biomarker To Determine Risk of Congenital CMV Infection in Pregnant Women. *J Clin Microbiol*. 2016; 54(8): 2149–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 29. **F** Bialas KM, Tanaka T, Tran D, *et al.*: Maternal CD4⁺ T cells protect against severe congenital cytomegalovirus disease in a novel nonhuman primate model of placental cytomegalovirus transmission. *Proc Natl Acad Sci U S A*. 2015; 112(44): 13645–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 30. Forsgren M: Prevention of congenital and perinatal infections. *Euro Surveill*. 2009; 14(9): 2–4.
[PubMed Abstract](#)
 31. Rahav G: Congenital cytomegalovirus infection—a question of screening. *Isr Med Assoc J*. 2007; 9(5): 392–4.
[PubMed Abstract](#)
 32. Yinon Y, Farine D, Yudin MH: Screening, diagnosis, and management of cytomegalovirus infection in pregnancy. *Obstet Gynecol Surv*. 2010; 65(11): 736–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. Liesnard C, Donner C, Brancart F, *et al.*: Prenatal diagnosis of congenital cytomegalovirus infection: prospective study of 237 pregnancies at risk. *Obstet Gynecol*. 2000; 95(6 Pt 1): 881–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Bodeus M, Hubinont C, Bernard P, *et al.*: Prenatal diagnosis of human cytomegalovirus by culture and polymerase chain reaction: 98 pregnancies leading to congenital infection. *Prenat Diagn*. 1999; 19(4): 314–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Donner C, Liesnard C, Brancart F, *et al.*: Accuracy of amniotic fluid testing before 21 weeks' gestation in prenatal diagnosis of congenital cytomegalovirus infection. *Prenat Diagn*. 1994; 14(11): 1055–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Enders G, Bäder U, Lindemann L, *et al.*: Prenatal diagnosis of congenital cytomegalovirus infection in 189 pregnancies with known outcome. *Prenat Diagn*. 2001; 21(5): 362–77.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Gouarin S, Gault E, Vabret A, *et al.*: Real-time PCR quantification of human cytomegalovirus DNA in amniotic fluid samples from mothers with primary infection. *J Clin Microbiol*. 2002; 40(5): 1767–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 38. Lipitz S, Yagel S, Shalev E, *et al.*: Prenatal diagnosis of fetal primary cytomegalovirus infection. *Obstet Gynecol*. 1997; 89(5 Pt 1): 763–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Mulongo KN, Lamy ME, van Lierde M: Requirements for diagnosis of prenatal cytomegalovirus infection by amniotic fluid culture. *Clin Diagn Virol*. 1995; 4(3): 231–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Revello MG, Gerna G: Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. *Clin Microbiol Rev*. 2002; 15(4): 680–715.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 41. Lazzarotto T, Guerra B, Gabrielli L, *et al.*: Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy. *Clin Microbiol Infect*. 2011; 17(9): 1285–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. **F** Bilavsky E, Pardo J, Attias J, *et al.*: Clinical Implications for Children Born With Congenital Cytomegalovirus Infection Following a Negative Amniocentesis. *Clin Infect Dis*. 2016; 63(1): 33–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 43. **F** Tabata T, Pelitt M, Fang-Hoover J, *et al.*: Cytomegalovirus impairs cytotrophoblast-induced lymphangiogenesis and vascular remodeling in an *in vivo* human placental model. *Am J Pathol*. 2012; 181(5): 1540–59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 44. **F** Tabata T, Pelitt M, Zydek M, *et al.*: Human cytomegalovirus infection interferes with the maintenance and differentiation of trophoblast progenitor cells of the human placenta. *J Virol*. 2015; 89(9): 5134–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 45. Gabrielli L, Bonasoni MP, Santini D, *et al.*: Congenital cytomegalovirus infection: patterns of fetal brain damage. *Clin Microbiol Infect*. 2012; 18(10): E419–27.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. **F** Tabata T, Pelitt M, Fang-Hoover J, *et al.*: Persistent Cytomegalovirus Infection in Amniotic Membranes of the Human Placenta. *Am J Pathol*. 2016; 186(11): 2970–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 47. **F** van Zuylen WJ, Ford CE, Wong DD, *et al.*: Human Cytomegalovirus Modulates Expression of Noncanonical Wnt Receptor ROR2 To Alter Trophoblast Migration. *J Virol*. 2015; 90(2): 1108–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 48. **F** Hamilton ST, Scott G, Naing Z, *et al.*: Human cytomegalovirus-induces cytokine changes in the placenta with implications for adverse pregnancy outcomes. *PLoS One*. 2012; 7(12): e52899.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 49. **F** Weisblum Y, Panet A, Zakay-Rones Z, *et al.*: Human cytomegalovirus induces a distinct innate immune response in the maternal-fetal interface. *Virology*. 2015; 485: 289–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 50. **F** Cannon MJ, Griffiths PD, Aston V, *et al.*: Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit? *Rev Med Virol*. 2014; 24(5): 291–307.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 51. **F** Boppana SB, Ross SA, Novak Z, *et al.*: Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. *JAMA*. 2010; 303(14): 1375–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 52. de Vries JJ, Claas EC, Kroes AC, *et al.*: Evaluation of DNA extraction methods for dried blood spots in the diagnosis of congenital cytomegalovirus infection. *J Clin Virol*. 2009; 46(Suppl 4): S37–42.
[PubMed Abstract](#) | [Publisher Full Text](#)

53. Vauloup-Fellous C, Ducroux A, Couloigner V, *et al.*: **Evaluation of cytomegalovirus (CMV) DNA quantification in dried blood spots: retrospective study of CMV congenital infection.** *J Clin Microbiol.* 2007; **45**(11): 3804–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Atkinson C, Emery VC, Griffiths PD: **Development of a novel single tube nested PCR for enhanced detection of cytomegalovirus DNA from dried blood spots.** *J Virol Methods.* 2014; **196**: 40–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. **F** Boppana SB, Ross SA, Shimamura M, *et al.*: **Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns.** *N Engl J Med.* 2011; **364**(22): 2111–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
56. Doyle M, Atkins JT, Rivera-Matos IR: **Congenital cytomegalovirus infection in infants infected with human immunodeficiency virus type 1.** *Pediatr Infect Dis J.* 1996; **15**(12): 1102–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Kovacs A, Schluchter M, Easley K, *et al.*: **Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group.** *N Engl J Med.* 1999; **341**(2): 77–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Slyker JA, Lohman-Payne BL, John-Stewart GC, *et al.*: **Acute cytomegalovirus infection in Kenyan HIV-infected infants.** *AIDS.* 2009; **23**(16): 2173–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Roxby AC, Atkinson C, Asbjörnsdóttir K, *et al.*: **Maternal valacyclovir and infant cytomegalovirus acquisition: a randomized controlled trial among HIV-infected women.** *PLoS One.* 2014; **9**(2): e87855.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. **F** Leruez-Ville M, Ghout I, Bussi eres L, *et al.*: **In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study.** *Am J Obstet Gynecol.* 2016; **215**(4): 462.e1–462.e10.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
61. Slyker JA, Richardson B, Chung MH, *et al.*: **Maternal Highly Active Antiretroviral Therapy Reduces Vertical Cytomegalovirus Transmission But Does Not Reduce Breast Milk Cytomegalovirus Levels.** *AIDS Res Hum Retroviruses.* 2016.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. **F** Kimberlin DW, Jester PM, S anchez PJ, *et al.*: **Valganciclovir for symptomatic congenital cytomegalovirus disease.** *N Engl J Med.* 2015; **372**(10): 933–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
63. Kimberlin DW, Lin CY, S anchez PJ, *et al.*: **Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial.** *J Pediatr.* 2003; **143**(1): 16–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Rawlinson WD, Boppana S, Fowler KB, *et al.*: **Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy.** *Lancet Infect Dis.* 2016. (in press).
65. Griffiths PD, McLean A, Emery VC: **Encouraging prospects for immunisation against primary cytomegalovirus infection.** *Vaccine.* 2001; **19**(11–12): 1356–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. **F** Griffiths PD: **Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation.** *Lancet Infect Dis.* 2012; **12**(10): 790–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
67. **F** Pass RF, Zhang C, Evans A, *et al.*: **Vaccine prevention of maternal cytomegalovirus infection.** *N Engl J Med.* 2009; **360**(12): 1191–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
68. **F** Schleiss MR, Berka U, Watson E, *et al.*: **Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.** *Clin Vaccine Immunol.* 2017; **24**(1): pii: e00300-16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
69. Revello MG, Lazzarotto T, Guerra B, *et al.*: **A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus.** *N Engl J Med.* 2014; **370**(14): 1316–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
70. Nigro G, Adler SP, La Torre R, *et al.*: **Passive immunization during pregnancy for congenital cytomegalovirus infection.** *N Engl J Med.* 2005; **353**(13): 1350–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
71. **F** Hamilton ST, van Zuylen W, Shand A, *et al.*: **Prevention of congenital cytomegalovirus complications by maternal and neonatal treatments: a systematic review.** *Rev Med Virol.* 2014; **24**(6): 420–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**

Open Peer Review

Current Referee Status:



Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The referees who approved this article are:

Version 1

- David Abate**, Department of Molecular Medicine, University of Padua, Padua, Italy
Competing Interests: No competing interests were disclosed.
- William Rawlinson**, ^{1,2} ¹ Serology & Virology Division, SEALS Microbiology, NSW Health Pathology, Prince of Wales Hospital, Sydney, Australia
² School of Medical Sciences and School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia
Competing Interests: No competing interests were disclosed.